Company News - Q Technology (01478.HK) reported a total sales volume of camera modules of 44.071 million units in January, representing a year-on-year increase of 22.8%. Fingerprint recognition module sales reached 19.741 million units, up 18.4% year-on-year, driven by increased overseas customer demand and a growing market share in the IoT and smart automotive sectors [2] - China Resources Power (00836.HK) achieved a sales volume of 23.78879 million megawatt-hours in January, a year-on-year increase of 28.4%. The sales from wind power plants increased by 7.2%, while solar power plant sales surged by 72.3% year-on-year [2] - NetEase-S (09999.HK) projected net revenue of approximately 112.626 billion yuan for 2025, a year-on-year growth of 6.96%, with net profit expected to be around 33.76 billion yuan, up 13.68% [2] - NetEase Cloud Music (09899.HK) anticipates revenue of about 7.759 billion yuan in 2025, with an expected profit of approximately 2.746 billion yuan, reflecting a significant year-on-year growth of 75.4%. The gross margin is expected to reach 35.7%, an increase from 33.7% in 2024, attributed to business scale growth, enhanced monetization capabilities, prudent cost management, and operational leverage [2] - Huitian Group (00806.HK) expects to achieve a consolidated profit attributable to shareholders of approximately 660 million HKD for the fiscal year 2025, a substantial increase from 31 million HKD in the previous year [2] Biotech Developments - Reborn Bio-B (06938.HK) entered into an exclusive global licensing agreement with Madrigal for several siRNA assets, receiving an upfront payment of 60 million USD, with potential cumulative payments of up to 4.4 billion USD upon achieving certain development, regulatory, and commercialization milestones, in addition to potential royalties on net sales [3] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase 1b/2 clinical study of HLX43 in combination with HLX07 or Hansizhuang® for patients with advanced or metastatic colorectal cancer in China [3] - Heng Rui Medicine (01276.HK) announced that its injection of Rukang Trastuzumab has been included in the list of breakthrough therapies, with global sales of similar products expected to reach approximately 6.557 billion USD in 2024 [3] - Saint Bella (02508.HK) made significant progress in its global strategic expansion plan, aiming to extend its reach to the eastern United States, the UK, France, Thailand, and Australia [3] - China National Biotech Group (08247.HK) signed a strategic cooperation agreement with Xiaoshou Medical to jointly promote the enhancement of quality medical resources and grassroots medical service capabilities [3] Buyback Activities - Geely Automobile (00175.HK) repurchased 1.201 million shares at a cost of 20.3042 million HKD, with repurchase prices ranging from 16.67 to 17.08 HKD [4] - Bairong Cloud-W (06608.HK) repurchased 1.66 million shares for 18.9051 million HKD, with share prices between 11.11 and 11.43 HKD [5] - Kingsoft (03888.HK) repurchased 355,200 shares at a cost of 9.9963 million HKD, with repurchase prices ranging from 27.9 HKD to 28.2 HKD [5]

格隆汇2月11日丨复宏汉霖(02696.HK)宣布，近日，注射用HLX43(靶向PD-L1抗体偶联药物) (「HLX43」)联合HLX07(重组抗EGFR人源化单克隆抗体注射液)(「HLX07」)或汉斯状®(斯鲁利单抗注 射液)(「汉斯状®」)在晚期或转移性结直肠癌患者中开展的1b/2期临床研究于中国大陆完成首例患者给 药。 本研究为一项1b/2期临床研究，旨在评估HLX43联合HLX07或汉斯状®，在晚期或转移性结直肠癌患者 中的安全性、耐受性和有效性。该研究包括两个部分：第一部分包括第一阶段(安全导入期)和第二阶段 (剂量扩展)。第一阶段采用3+3剂量递增设计，患者将接受HLX43 2.5 mg/kg或3.0 mg/kg，联合固定剂量 HLX07(1000 mg)每三周一次(Q3W)静脉输注给药。第一阶段主要目的为评估不同剂量水准HLX43联合 HLX07在晚期或转移性结直肠癌患者中的安全性和耐受性，次要目的是研究HLX43的药代动力学(PK) 特徵和免疫原性、疗效、潜在药效学、潜在预测性或耐药性生物标志物。第二阶段是随机、多中心、开 放标签研究，HLX43两个剂量水准分别联合固定剂量HLX07进行扩展， ...

智通财经APP讯，复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物) ("HLX43")联 合 HLX07(重组抗EGFR人源化单克隆抗体注射液)(" HLX07")或汉斯状®(斯鲁利单抗注射 液)("汉斯状®")在晚期或转移性结直肠癌患者中开展的1b/2期临床研究于中国境内(不包括中国港澳台地 区，下同)完成首例患者给药。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 注射用HLX43（靶向PD-L1抗體偶聯藥物） 聯合HLX07（重組抗EGFR人源化單克隆抗體注射液） 或漢斯狀® （斯魯利單抗注射液） 在晚期或轉移性結直腸癌患者中開展的1b/2期臨床研究 於中國境內完成首例患者給藥 A. 緒言 1 料，暫定HLX43的劑量水準為2.5 mg/kg和3.0 mg/kg，該階段主要目的是研究不 同劑量HLX43聯合固定劑量HLX07在轉移性結直腸癌(mCRC)患者中的有效性， 次要目的包括評價其安全性和耐受性、HLX43的PK特徵和免疫原性、並研究潛在 預測性或耐藥性生物標誌物。第二部分為一項隨機、多中心、開放標籤研究，評 估HLX43 2.0 mg/kg或2.5 mg/kg聯合固定劑量漢斯狀®(30 ...

Core Viewpoint - The stock of Fuhong Hanlin (02696) rose nearly 5% in early trading, reflecting positive market sentiment following recent developments in clinical research and regulatory approvals [1] Group 1: Clinical Research Developments - Fuhong Hanlin successfully held an offline investigator meeting in San Francisco, focusing on the international multicenter Phase III clinical study HLX22-GC-301, which investigates the combination of the new anti-HER2 monoclonal antibody HLX22 with trastuzumab and chemotherapy for first-line treatment of HER2-positive advanced gastric cancer [1] - The company announced the approval from the National Medical Products Administration for clinical trials of HLX43 in combination with HLX07 and surufatinib for the treatment of advanced solid tumors, with plans to initiate a Phase II clinical study in China once conditions are met [1]

消息面上，复宏汉霖宣布，收到国家药监局关于同意注射用HLX43联合HLX07及斯鲁利单抗注射液用 于晚期实体瘤治疗开展临床试验的批准。复宏汉霖计划在条件具备后于中国境内开展该联合治疗方案的 II期临床研究。 复宏汉霖(02696)早盘涨超4%，截至发稿，涨3.48%，报56.5港元，成交额1265.25万港元。 公开资料显示，HLX43为复宏汉霖利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子 与其自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物(ADC)，拟用于治疗晚期/ 转移性实体瘤；HLX07为复宏汉霖自主研发的针对EGFR靶点的创新型生物药，拟用于治疗晚期实体 瘤；斯鲁利单抗注射液为复宏汉霖自主研发的创新型抗PD-1单抗。 ...

消息面上，复宏汉霖宣布，收到国家药监局关于同意注射用HLX43联合HLX07及斯鲁利单抗注射液用 于晚期实体瘤治疗开展临床试验的批准。复宏汉霖计划在条件具备后于中国境内开展该联合治疗方案的 II期临床研究。 公开资料显示，HLX43为复宏汉霖利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子 与其自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物（ADC），拟用于治疗晚 期/转移性实体瘤；HLX07为复宏汉霖自主研发的针对EGFR靶点的创新型生物药，拟用于治疗晚期实体 瘤；斯鲁利单抗注射液为复宏汉霖自主研发的创新型抗PD-1单抗。 智通财经APP获悉，复宏汉霖(02696)早盘涨超4%，截至发稿，涨3.48%，报56.5港元，成交额1265.25万 港元。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of a new treatment regimen for advanced solid tumors, which includes HLX43 and HLX07 [1] Group 1 - The approved treatment regimen consists of HLX43, a PD-L1 targeted antibody conjugate, and HLX07, a recombinant humanized monoclonal antibody targeting EGFR, both classified as Class 1 therapeutic biological products [1] - The clinical trials for this treatment plan will be conducted in China, with Phase II studies planned once conditions are met [1] - The regimen also includes the use of Surufatinib injection, marketed in China under the name Hansizhuang® [1]

复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物)(HLX43)联合HLX07(重组抗 EGFR人源化单克隆抗体注射液)(HLX07)及汉斯状® (斯鲁利单抗注射液)(汉斯状®)用于晚期实体瘤治疗 的临床试验申请获国家药品监督管理局(NMPA)批准。公司拟于条件具备后于中国境内开展相关临床试 验。 HLX43的1期临床数据于2025美国临床肿瘤学会(ASCO)年会及2025年世界肺癌大会(WCLC)上先后发 布，在非小细胞肺癌(NSCLC)等实体瘤中展现出良好的安全性及令人鼓舞的初步疗效。HLX07为公司自 主研发的针对EGFR靶点的创新型生物药，计划用于晚期实体瘤治疗。2023年2月，HLX07联合化疗用 于晚期实体瘤治疗的1b/2期临床研究结果显示其安全性及耐受性良好。汉斯状®为公司自主开发的创新 型抗PD-1单抗，其于中国境内(不包括中国港澳台地区，下同)已获批上市的适应症包括联合化疗一线治 疗鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC) 及非鳞状非小 细胞肺癌(nsqNSCLC)，2025年12月，汉斯状® (斯鲁 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for clinical trial applications of HLX43 in combination with HLX07 and Hanshuo® for the treatment of advanced solid tumors [1][2] Group 1: Clinical Trial Approvals - The clinical trial application for HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hanshuo® has been approved by NMPA [1] - The company plans to conduct the relevant clinical trials within China once conditions are met [1] Group 2: Clinical Data and Product Development - Phase 1 clinical data for HLX43 will be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and the 2025 World Lung Cancer Conference (WCLC), showing promising safety and preliminary efficacy in non-small cell lung cancer (NSCLC) and other solid tumors [2] - HLX07, an innovative biopharmaceutical targeting EGFR, has shown good safety and tolerability in a 1b/2 phase clinical study for advanced solid tumors conducted in February 2023 [2] - Hanshuo®, an innovative anti-PD-1 monoclonal antibody developed by the company, has been approved for multiple indications in mainland China, including first-line treatment for squamous NSCLC and extensive-stage small cell lung cancer [2] - The New Drug Application (NDA) for Hanshuo® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been accepted by NMPA and is under priority review [2]